In SpA pts with lower activity by SPARCC score significant correlation between Dkk-1 and inflammatory lesions in SIJ (r=0.400, p=0.043) and a negative correlation between Dkk-1 and BASDAI (r=-0.513, p=0.017) were found. There was no correlation between Scl and Dkk-1 levels among all pts and different subgroups. Conclusions: Scl level is significantly higher in pts with lower disease activity by SPARCC MRI SIJ score and ASDAS-CRP. Dkk-1 significantly positively correlates with disease activity due to CRP level and SPARCC score, but not to BASDAI. Background: TNF inhibitors (TNFi), are effective in controlling the activity of spondyloarthritis. But, there is a proportion of patients, who have to stop treatment due to its ineffectiveness or to the appearance of adverse events. In addition, these therapies imply high economic costs. To identify predictors of response, would help us to make decisions and to improve the risk/benefit ratio, in patients candidates who are candidates to initiate TNFi Objectives: To determine clinical, biological and genetic predictors of nonresponse to treatment with TNFi in patients with AS and PsA. Methods: We analyzed 118 patients [49 AS and 69 PsA (24 axial and peripheral involvement and 45 only peripheral)], under treatment or who were to start treatment with TNFi. Data were collected, prior to the start of the TNFi and at the last scheduled visit to the Rheumatology Service of the Hospital Puerta de Hierro, during the period 2013-2014. A clinical response was defined as the reduction ≥50% of the initial BASDAI, in patient with axial involvement, and if the final DAS 28 PCR was <2.6, in those patients with only peripheral involvement. A total of 73 men and 45 woman, mean age 53±11.2 years, and a median duration of illness of 15 years (IQR 10-23) were included. The baseline ESR and CRP were (10mm/hr IQR 5.0-27.0 and 2mg/l IQR 0.0-9.0) respectively. The mean and SD of BASDAI, DAS28 CPR and BASFI were (6.0±1.9, 3
Conclusions: Female gender, basal BASFI elevated and SNP rs11591741 (GG) of CHUCK gene were identified as predictors of nonresponse to TNFi treatment in these patients.
